Nova Tina Susan 4

What Happened
Nova Tina Susan, a director of Aurinia Pharmaceuticals (AUPH), was granted 23,931 derivative shares (recorded as an acquisition at $0.00) on June 4, 2026. The grant shows an acquisition price of $0.00 (no cash paid at grant). This is an award/derivative grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-04; Form 4 filed: 2026-06-08 (timely filed within the SEC’s two-business-day window).
• Transaction type/code: A — Grant/Award (derivative), 23,931 shares, $0.00 per share.
• Shares owned after transaction: Not specified in the provided Form 4 summary.
• Footnote: The securities (options) "shall vest one year from date of grant."
• No sale or cash exercise reported; this is an award subject to future vesting.

Context
This was an award of derivative securities (stock options or similar) to a company director. Such awards typically vest over time (here, one year) and do not represent an immediate purchase or sale; they do not necessarily indicate the director’s near-term trading intentions.